R
Raghunadharao Digumarti
Researcher at Nizam's Institute of Medical Sciences
Publications - 111
Citations - 5889
Raghunadharao Digumarti is an academic researcher from Nizam's Institute of Medical Sciences. The author has contributed to research in topics: Myeloid leukemia & Population. The author has an hindex of 25, co-authored 108 publications receiving 5456 citations.
Papers
More filters
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Journal ArticleDOI
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Peter G. Pappas,Coleman Rotstein,Robert F. Betts,Marcio Nucci,Deepak Talwar,Jan J. De Waele,Jose A. Vazquez,Bertrand Dupont,David Horn,Luis Ostrosky-Zeichner,Annette C. Reboli,Byungse Suh,Raghunadharao Digumarti,Chunzhang Wu,Laura L. Kovanda,Leah J. Arnold,Donald N. Buell +16 more
TL;DR: Dosages of micafungin 100 mg daily and 150 mg daily were noninferior to a standard dosage of caspofungin for the treatment of candidemia and other forms of invasive candidiasis.
Journal ArticleDOI
The growing burden of cancer in India: epidemiology and social context
Mohandas K. Mallath,David G. Taylor,Rajendra A. Badwe,Goura Kishor Rath,Viswanathan Shanta,C S Pramesh,Raghunadharao Digumarti,P Sebastian,Bibhuti Bhusan Borthakur,Ashok Kalwar,Sanjay Kapoor,Shaleen Kumar,Jennifer Gill,Moni Abraham Kuriakose,Hemant Malhotra,Suresh C. Sharma,Shilin Shukla,Lokesh Viswanath,Raju Titus Chacko,Jeremy Pautu,K.S. Reddy,Kailash S Sharma,Arnie Purushotham,Richard Sullivan +23 more
TL;DR: This first of three papers examines the complex epidemiology of cancer, the future burden, and the dominant sociopolitical themes relating to cancer in India.
Journal Article
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (vol 45, pg 883, 2007)
Pg Pappas,Cmf Rotstein,Rf Betts,Marisa R. Nucci,Deepak Talwar,Jan J. De Waele,Ja Vazquez,Bf Dupont,Dl Horn,Luis Ostrosky-Zeichner,Ac Reboli,Byungse Suh,Raghunadharao Digumarti,Chunzhang Wu,Ll Kovanda,Lj Arnold,Dn Buell +16 more
TL;DR: In this article, the authors compared micafungin and caspofungin with a standard dosage of 50 mg followed by 100 mg for the treatment of invasive candidiasis.
Journal ArticleDOI
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge E. Cortes,Jeffrey H. Lipton,Delphine Rea,Raghunadharao Digumarti,Charles Chuah,Nisha Nanda,Annie Claude Benichou,Adam R. Craig,Mauricette Michallet,Franck E. Nicolini,Hagop M. Kantarjian +10 more
TL;DR: Omacetaxine may provide a safe and effective treatment for CML patients with T315I mutation and this phase 2 trial assessed the efficacy of omacetaxine in C ML patients withT315I and tyrosine kinase inhibitor failure.